Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants

British Journal of Ophthalmology

Volumn 88, Issue 4, 2004, Pages 450-454

  Hopley, C ^a   Salkeld, G ^b   Wang, J J ^a   Mitchell, P ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BENZOPORPHYRIN DERIVATIVE; ZINC;

ADULT; AGED; ARTICLE; BLINDNESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG MEGADOSE; EARLY DIAGNOSIS; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; RETINA MACULA AGE RELATED DEGENERATION; SCREENING; UNITED KINGDOM; VISUAL IMPAIRMENT;

AGED; ANTIOXIDANTS; AUSTRALIA; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; FEMALE; HUMANS; INCIDENCE; MACULAR DEGENERATION; MALE; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; ZINC;

EID: 1842505395     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2003.035279     Document Type: Article

References (32)

1. Bishop BMP. The national strategy for on ageing australia, healthy ageing, Discussion Paper. 1-24. Canberra: Commonwealth of Australia, 1999.
2. Wang JJ, Foran S, Mitchell P. Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye Study. Clin Exp Ophthalmol 2000;28:268-73.
3. Owen CG, Fletcher AE, Donoghue M, et al. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol 2003;87:312-7.
4. Wright SE, Keeffe JE, Thies LS. Direct costs of blindness in Australia [in process citation]. Clin Exp Ophthalmol 2000;28:140-2.
5. Chiang YP, Bassi LJ, Javitt JC. Federal budgetary costs of blindness. Milbank Q 1992;70:319-40.
6. Wang JJ, Mitchell P, Smith W, et al. Impact of visual impairment on use of community support services by elderly persons: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 1999;40:12-19.
7. Moisseiev J, Alhalel A, Masuri R, et al. The impact of the macular photocoagulation study results on the treatment of exudative age-related macular degeneration. Arch Ophthalmol 1995;113:185-9.
8. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 1999;117:1329-45.
9. Meads C, Salas C, Roberts T, et al. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2003;7:1-108.
10. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology 2001;108:697-704.
11. Mitchell P, Wang JJ, Smith W, et al. Smoking and the 5-year incidence of age-related maculopothy: the Blue Mountains Eye Study. Arch Ophthalmol 2002;120:1357-63.
12. Mitchell P, Chapman S, Smith W. "Smoking is a major cause of blindness." A new cigarette pocket warning? Med J Aust 1999;171:173-4.
13. White V, Hill D, Siahpush M, et al. How has the prevalence of cigarette smoking changed among Australian adults? Trends in smoking prevalence between 1980 and 2001. Tobacco Control 2003;12(Suppl 2):II67-74.
14. MMWR. Prevalence of current cigarette smoking among adults and changes in prevalence of current and some day smoking - United States, 1996-2001. Mort Mortal Wkly Rep 2003;52:303-7.
15. Marques-Vidal P, Ruidavets JB, Cambou JP, et al. Changes and determinants in cigarette smoking prevalence in southwestern France, 1985-1997. Eur J Public Health 2003;13:168-70.
16. AREDS report no 8. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol 2001;119:1417-36.
17. Barratt A, Irwig L, Glasziou P, et al. Users' guides to the medical literature: XVII. How to use guidelines and recommendations about screening. Evidence-Based Medicine Working Group. JAMA 1999;281:2029-34.
18. Foran S, Wang JJ, Mitchell P. Causes of incident visual impairment: the Blue Mountains Eye Study. Arch Ophthalmol 2002;120:613-19.
19. McLennan W. Australian statistician. Population projections: 1997 to 2051. 1-130. Canberra: Australian Bureau of Statistics, 1998.
20. Australian Bureau of Statistics. Deaths Australia 1996. ABS Catalogue 3302.0, 62-63. Canberra: ABS, 1997.
21. Sharma S, Brown GC, Brown MM, et al. Converting visual acuity to utilities. Can J Ophthalmol 2000;35:267-72.
22. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes, 2nd ed. New York: Oxford University Press, 1997.
23. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - modeling studies. Value Health 2003;6:9-17.
24. Mitchell P, Smith W, Attebo K, et al. Prevalence of age-related maculopothy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995;102:1450-60.
25. Brown GC, Sharma S, Brown MM, et al. Utility values and age-related macular degeneration. Arch Ophthalmol 2000;118:47-51.
26. Brown MM, Brown GC, Sharma S, et al. Quality of life with visual acuity loss from diabetic retinopothy and age-related macular degeneration. Arch Ophthalmol 2002; 120:481-4.
27. Brown MM, Brown GC, Sharma S, et al. Health care economic analyses and value-based medicine. Surv Ophthalmol 2003;48:204-23.
28. Sharma S, Oliver-Fernandez A, Bakal J, et al. Utilities associated with diabetic retinopothy: results from a Canadian sample. Br J Ophthalmol 2003;87:259-61.
29. Brown MM, Brown GC, Sharma S, et al. Utility values associated with blindness in an adult population. Br J Ophthalmol 2001;85:327-31.
30. Brown GC, Brown MM, Sharma S, et al. The reproducibility of ophthalmic utility values. Trans Am Ophthalmol Soc 2001;99:199-203.
31. Younis N, Broadbent DM, Vora JP, et al. Incidence of sight-threatening retinopothy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003;361:195-200.
32. Loupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.